
Opinion|Videos|September 29, 2023
Safety Outcomes with Leuprolide
Author(s)Paul Sieber, MD
In the second interview of the series, Paul Sieber, MD, provides expert insights on the management of adverse effects seen in patients receiving leuprolide for the treatment of advanced/metastatic prostate cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
BOND-003 Cohort C: Efficacy Results
5
















